R&D expense · 2019–2025

Keros Therapeutics R&D expense

$130M−25.3% · FY2025

Keros Therapeutics (KROS) reported $130M in R&D expense for fiscal 2025, −25.3% year on year.

$17.4M2019$33.9M2020$55.1M2021$87.3M2022$135M2023$174M2024$130M2025
Keros Therapeutics — R&D expense, 2019–2025
Fiscal yearR&D expenseChangeFiling
FY20252025-12-31$130M−25.3%Open →
FY20242024-12-31$174M+28.4%Open →
FY20232023-12-31$135M+55.0%Open →
FY20222022-12-31$87.3M+58.3%Open →
FY20212021-12-31$55.1M+62.9%Open →
FY20202020-12-31$33.9M+94.8%Open →
FY20192019-12-31$17.4M—Open →

R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.

Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2019–2025 compound annual growth +39.8%

R&D expense at companies of similar size

Full ranking by R&D expense →

Cite this page

Ready-made references for the figures on this page, as published on September 25, 2026.

Wikipedia

{{cite web |title=Keros Therapeutics R&D expense |url=https://companiesranked.com/en/company/keros-therapeutics/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}

APA 7

CompaniesRanked. (September 25, 2026). Keros Therapeutics R&D expense. CompaniesRanked. https://companiesranked.com/en/company/keros-therapeutics/research-and-development-expense

BibTeX

@misc{companiesranked-en-company-keros-therapeutics-research-and-development-expense-2026,
  author       = {{CompaniesRanked}},
  title        = {{Keros Therapeutics R\&D expense}},
  year         = {2026},
  howpublished = {\url{https://companiesranked.com/en/company/keros-therapeutics/research-and-development-expense}},
  note         = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
  urldate      = {2026-09-25}
}

The filing itself

The numbers above are read from this document: 10-K · 0001664710-26-000018 · March 4, 2026

{{cite web |title=Keros Therapeutics R&D expense — 10-K (0001664710-26-000018) |url=https://www.sec.gov/Archives/edgar/data/1664710/000166471026000018/kros-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-04}}

The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.

← Keros Therapeutics overview